<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3043">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01741701</url>
  </required_header>
  <id_info>
    <org_study_id>13397</org_study_id>
    <nct_id>NCT01741701</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Oxaloacetate in Subjects With Treated PD</brief_title>
  <official_title>A Pilot Double-Blind, Parallel Group, Placebo Controlled Study of Oxaloacetate in Subjects With Treated Parkinson's Disease (PD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Terra Biological LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Oxaloacetate (OAA) is a safe and effective
      treatment for Parkinson's disease. Each subject will be asked to make 3 study visits and
      complete two safety follow-up phone calls over a 4 month period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>safety profile of study drug</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate subject safety through data collection with various tests and procedures which include vital signs (blood pressure, heart rate, temperature, respiratory rate, height and weight), number of patients with adverse events and type of adverse events, laboratory blood tests (chem 12 metabolic panel, CBC with differential, serum/plasma amino acids).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy of study drug</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the efficacy of study drug based on change in PD from baseline to 4 months.  Includes Unified Parkinson's Disease Rating Scale, Hoehn &amp; Yahr staging, Schwab and England, patient and clinician global impressions, PDQ-39 quality of life assessment, Montreal Cognitive Assessment, Geriatric Depression Scale, Nonmotor Symptoms Questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Oxaloacetate (OAA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsules that contain only 100 mg ascorbate, taken daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaloacetate (OAA)</intervention_name>
    <arm_group_label>Oxaloacetate (OAA)</arm_group_label>
    <other_name>benaGeneâ„¢</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to give informed consent and follow instructions per the protocol

          -  Diagnosis of idiopathic PD within 7 years of diagnosis

          -  Taking stable doses of levodopa and would not predictably need adjustment in PD
             medications for 4 months

          -  Unified Parkinson's Disease Rating Scale (UPDRS) II + III at least 30 points at
             baseline

        Exclusion Criteria:

          -  Previously taken Oxaloacetate

          -  Participation in other drug studies or use of other investigational products within
             30 days prior to baseline

          -  In the Investigator's opinion, any unstable or clinically significant condition that
             would impair the subjects' ability to comply with study follow-up

          -  Other known or suspected cause of parkinsonism
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajesh Pahwa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly Lyons, PhD</last_name>
    <phone>(913) 588-7159</phone>
    <email>klyons@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Lyons, PhD</last_name>
      <phone>913-588-7159</phone>
      <email>klyons@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Rajesh Pahwa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>December 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas</investigator_affiliation>
    <investigator_full_name>Rajesh Pahwa, MD</investigator_full_name>
    <investigator_title>Professor, Director PD and Movement Disorder Center</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
